

GeneType Corporation

[View the current GeneType Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/4426-GeneType+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/4426-GeneType+Corporation.html>)

Contact Details:

Tel: 415 3421493

Fax: 415 344 0233

Email:

CA

United States of America

Recent Publications by GeneType Corporation:



- [Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.](#)
*For the past 15 years cationic liposomes have routinely been utilised for...*18th February, 2005
GeneType Research Labs, 60-70 Hanover Street, 3065 Fitzroy, Australia.- J Mol Med. 2004 Sep;82(9):579-91. Epub 2004 Jun 23. ([DOI Direct Link](#))
- [Tumour angiogenesis, vascular biology and enhanced drug delivery.](#)
*It is now common knowledge that for a solid tumour to become...*31st December, 2004
GeneType Research- J Drug Target. 2004 Jun;12(5):245-55. ([DOI Direct Link](#))
- [Deoxyribozymes: cleaving a path to clinical trials.](#)
*Deoxyribozymes (DNAzymes) comprise an exciting class of nucleic acid...*16th December, 2004
GeneType Research Laboratories, 60 Hanover Street, Fitzroy 3065, Victoria,- Trends Pharmacol Sci. 2004 Aug;25(8):395-7. ([DOI Direct Link](#))
- [Erythropoiesis from adult but not fetal blood-derived CD133+ stem cells depends strongly on interleukin-3.](#)
*We have shown previously that erythropoiesis in cultures from fetal blood...*16th November, 2004
Genetic Technologies Pty Ltd., Melbourne, Australia.- Growth Factors. 2004 Mar;22(1):45-50.
- [IL-3-dependent early erythropoiesis is stimulated by autocrine transforming growth factor beta.](#)
*Autocrine/paracrine transforming growth factor beta (TGF-beta) is an...*13th November, 2004
Genetic Technologies Pty Ltd., Melbourne, Australia.- Stem Cells. 2004;22(2):216-24.
- [Cyclodextrins and oligonucleotide delivery to solid tumours.](#)
*Cyclodextrins (CyDs) have traditionally been used for dissolving...*28th September, 2004
Genetic Technologies Pty. Ltd., Hanover St 3065 Fitzroy Australia.- J Drug Target. 2004 Jan;12(1):1-9.

([DOI Direct Link](#))

- [Reactivation of fetal hemoglobin in adult stem cell erythropoiesis by transforming growth factor-beta.](#)
Treatment of adult blood-derived stem cells with transforming growth... 21st June, 2004
GeneType Pty, Ltd., Melbourne, Victoria 3065, Australia.- J Hematother Stem Cell Res. 2003 Oct;12(5):499-504. ([DOI Direct Link](#))
- [Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature.](#)
In the past three decades, two very important findings regarding tumour... 9th March, 2004
Johnson & Johnson Research, Box 4555, Strawberry Hills 2012, Australia.- Int J Pharm. 2003 Nov 28;267(1-2):1-12.

GeneType Corporation Patents:



- 5789568- [Human leukocyte antigen \(HLA\) locus-specific primers](#)
- 5612179- [Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes](#)
- 5447842- [Fetal cell recovery method](#)
- 5192659- [Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes](#)
- 5153117- [Fetal cell recovery method](#)
- 5096557- [Internal standard for electrophoretic separations](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

